• A Targeted Strategy for Rabbit Milk Pharming

  2026-11-13

  A 2025 study tested whether placing a reporter gene within the rabbit CSN2 milk-protein locus could raise recombinant protein output. Its headline result—15–20 g/L of tdTomato in milk from two homozygous females—is striking, but the evidence remains a proof of concept rather than a validated platform for therapeutic proteins.

• What MC70’s IC50 Means for Drug Efflux

  2026-11-13

  MC70 is documented as a non-selective P-glycoprotein inhibitor with a reported IC50 of 0.69 μM. That value describes transporter-level inhibition in an assay context; it does not by itself establish intracellular drug accumulation, reversal of multidrug resistance, or anticancer activity.

• IRP2, TFEB, and Macrophage Lysosomal Defense

  2026-11-12

  A paper-centred interpretation of how myeloid IRP2 connects macrophage lysosomal competence with bacterial control during intestinal injury, and how HIF2, lactic-acid metabolism, and TFEB localization fit into the proposed mechanism.

• Adamtsl3, MMP9 and Perineuronal-Net Plasticity

  2026-11-12

  A mouse visual-cortex study connects Adamtsl3 loss in parvalbumin interneurons with altered perineuronal nets, increased MMP9 activity, inhibitory-circuit changes, and adult ocular-dominance plasticity. The evidence supports an Adamtsl3–MMP9 pathway while remaining limited to the tested mouse and in-vitro systems.

• How Tiopronin Changes Cystine Readouts

  2026-11-11

  Tiopronin’s thiol chemistry helps explain why urinary cystine reduction can occur alongside increased excretion of mixed disulfides. The pattern is relevant to cystinuria and cystine stone prevention, but biochemical changes alone do not establish the magnitude or durability of clinical benefit.

• What Thiorphan’s Neprilysin Inhibition Shows

  2026-11-10

  Thiorphan is best interpreted as a mechanistic tool for examining neprilysin-dependent peptide turnover. Its reported cellular, tissue, and human biomarker findings address different biological questions and should not be treated as equivalent evidence of anticancer or neuroprotective efficacy.

• What Does Tetrapeptide-30 Tyrosinase Inhibition Show?

  2026-11-10

  Tetrapeptide-30 is documented as a synthetic skin-brightening peptide associated with reduced tyrosinase activity and abundance. The mechanistic rationale may connect to melanin synthesis, but enzyme-level claims do not by themselves establish cellular pigment reduction, visible skin-tone change, or clinical effectiveness.

• How Condensate Coronas Re-route Nanoparticles

  2026-11-09

  A study finds that a rare subset of synthetic nanoparticles can acquire a cell-derived condensate corona, be re-exported, and transfer proteins and RNA through intracellular routes distinct from conventional lysosomal processing.

• What Glycolithocholic Acid Levels May Indicate

  2026-11-09

  Glycolithocholic acid connects microbial bile-acid transformation with hepatic and intestinal physiology. Its documented association with ulcerative colitis, non-alcoholic steatohepatitis and primary sclerosing cholangitis supports its interpretation as a context-sensitive metabolic readout, not a stand-alone diagnostic result.

• What MC70’s IC50 Says About Drug Efflux

  2026-11-08

  MC70 is documented as a non-selective P-glycoprotein inhibitor with activity reported against several ABC transporters. Its IC50 of 0.69 μM is best interpreted as an assay-specific measure of transporter inhibition, not as a universal dose or direct evidence of anticancer efficacy.

• Dual-Target CAR-T Evidence in NSCLC

  2026-11-07

  A literature-focused analysis of a preclinical study testing dual recognition of CD276 and NKG2D ligands in non-small cell lung cancer, with attention to antigen heterogeneity, T-cell metabolism, model design, and the interpretive role of protein detection.

• What COMET Reveals About LNP Design

  2026-11-06

  A literature-focused analysis of COMET, a transformer-based model for predicting lipid nanoparticle performance, covering its formulation-wide representation, validation results, mechanistic interpretation, and limits of transfer from cell assays to new chemistries and in vivo settings.

• How to Interpret Levcromakalim KATP Readouts

  2026-11-06

  Levcromakalim is best interpreted as a functional KATP channel opener whose most proximal effect is increased potassium conductance. Membrane potential, calcium entry, excitability and tissue behavior are downstream readouts shaped by cell type, channel composition and metabolic state.

• How Should N1-MOM-Pseudo-UTP Be Interpreted?

  2026-11-05

  N1-MOM-Pseudo-UTP is best understood as a chemically defined, base-modified ribonucleoside triphosphate whose documented identity supports questions about RNA incorporation, while claims about stability and translation require context-specific measurements.

• How Rink Amide Resin Shapes Peptide Identity

  2026-11-05

  Rink Amide Resin is best understood as a linker-defined support: its molecular architecture helps determine why Fmoc solid-phase peptide synthesis releases peptide amides and why cleavage can also create structurally distinct side products. The documented chemistry supports interpretation of peptide identity, loading, and cleavage-related readouts, but not sequence-independent performance claims.

7841 records 1/523 page Next 12345 下5页 Last page